AKBA Akebia Therapeutics Inc.

Akebia Therapeutics Announces Poster Presentations at NKF Spring Clinical Meetings 2025

Akebia Therapeutics Announces Poster Presentations at NKF Spring Clinical Meetings 2025

CAMBRIDGE, Mass., March 25, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it will present data at the (NKF SCM25), which will take place in Boston, MA from April 10-13, 2025.

Akebia-supported posters will be displayed at NKF SCM25 during Exhibit Hall hours.

  • Cardiovascular Risk in Patients With DD-CKD Randomized to Vadadustat vs Darbepoetin Alfa With or Without Cardiovascular Disease:



  • Vadadustat for Treatment of Anemia in Older vs Younger Patients With Dialysis-Dependent-CKD:

On Thursday, April 10, 2025 at 4:00 pm during at NKF SCM25, Dr. Wolfgang Winkelmayer will present a poster titled “Vadadustat for Treatment of Anemia in Older vs Younger Patients With Dialysis-Dependent-CKD.”

NKF SCM25 attendees can also visit Akebia at Booth #1121 in the Exhibit Hall.

About Akebia Therapeutics

Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at , which does not form a part of this release.

Akebia Therapeutics Contact

Mercedes Carrasco



EN
25/03/2025

Underlying

AKBAAkebia Therapeutics Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Akebia Therapeutics Inc.

 PRESS RELEASE
Free
AKBA Akebia Therapeu...

Akebia Therapeutics Announces Positive Opinion of European Medicines A...

Akebia Therapeutics Announces Positive Opinion of European Medicines Agency for XOANACYL®, an Oral Therapy for Chronic Kidney Disease Licensed to Averoa CAMBRIDGE, Mass., April 03, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the European Commission (EC) to approve XOANACYL® (Ferric Citrate as Coordination Complex) for the treatmen...

April 3, 2025 1 EN
 PRESS RELEASE
Free
AKBA Akebia Therapeu...

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rul...

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CAMBRIDGE, Mass., April 02, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted eight newly-hired employees options to purchase an aggregate of 73,325 shares of Akebia’s common stock on March 31, 2025. The options were granted as an inducement material to each employee entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exerci...

April 2, 2025 1 EN
 PRESS RELEASE
Free
AKBA Akebia Therapeu...

Akebia Therapeutics Announces Poster Presentations at NKF Spring Clini...

Akebia Therapeutics Announces Poster Presentations at NKF Spring Clinical Meetings 2025 CAMBRIDGE, Mass., March 25, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it will present data at the (NKF SCM25), which will take place in Boston, MA from April 10-13, 2025. Akebia-supported posters will be displayed at NKF SCM25 during Exhibit Hall hours. Cardiovascular Risk in Patients With DD-CKD Randomized to Vadadustat vs Darbepoetin Alfa With or Without Cardiovascular Diseas...

March 25, 2025 1 EN
 PRESS RELEASE
Free
AKBA Akebia Therapeu...

Akebia Therapeutics Announces Pricing of Public Offering of Common Sto...

Akebia Therapeutics Announces Pricing of Public Offering of Common Stock CAMBRIDGE, Mass., March 19, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (“Akebia”) (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the pricing of its underwritten public offering (the “Offering”) of 25,000,000 shares of its common stock at a public offering price of $2.00 per share. All shares are being offered by Akebia. The gross proceeds to Akebia from the Offering, before deducting underwriting discounts, commissions an...

March 20, 2025 1 EN
 PRESS RELEASE
Free
AKBA Akebia Therapeu...

Akebia Therapeutics Announces Proposed Public Offering of Common Stock

Akebia Therapeutics Announces Proposed Public Offering of Common Stock CAMBRIDGE, Mass., March 19, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (“Akebia”) (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it has commenced an underwritten public offering (the “Offering”). All shares are being offered by Akebia. In addition, Akebia expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock sold in the Offering at the public offering pr...

March 19, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch